10 Things Worth Pay...
Health Care: Drugs
Cytokinetics Inc. (CYTK: NASDAQ)
$0.88 -0.02 | -2.17%
06/04/12 - 03:59 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 4.00M | 2.58M | 81.54M | 12.42M |
| Cost of Sales | -1.30M | -1.90M | -2.02M | -2.46M |
| Gross Operating Profit | 5.30M | 4.48M | 83.56M | 14.88M |
| Selling, General, and Administrative Expenses | 13.59M | 14.20M | 15.63M | 15.08M |
| Research & Development | 37.18M | 38.01M | 39.84M | 53.95M |
| Operating Income before D & A (EBITDA) | -45.48M | -47.74M | 28.09M | -54.15M |
| Depreciation & Amortization | 1.30M | 1.90M | 2.02M | 2.46M |
| Interest Income | 0.00 | 335.00K | 593.00K | 3.20M |
| Other Income - Net | 208.00K | 0.00 | -1.58M | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -47.76M | -49.30M | 25.10M | -55.88M |
| Interest Expense | 104.00K | 163.00K | 409.00K | 491.00K |
| Pre-Tax Income | -47.86M | -49.46M | 24.69M | -56.37M |
| Income Taxes | 0.00 | -176.00K | 150.00K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -47.86M | -49.29M | 24.54M | -56.37M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -47.86M | -49.29M | 24.54M | -56.37M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -47.86M | -49.29M | 24.54M | -56.37M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-46.67M | -49.29M | 24.52M | -53.90M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -50.72M | -49.29M | 24.54M | -56.37M |
| Basic EPS from Continuing Ops. | -0.72 | -0.77 | 0.43 | -1.14 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.72 | -0.77 | 0.43 | -1.14 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.72 | -0.77 | 0.43 | -1.14 |
| Basic Normalized Net Income/Share | -0.70 | -0.77 | 0.43 | -1.09 |
| EPS fr Continuing Ops. | -0.72 | -0.77 | 0.42 | -1.14 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.72 | -0.77 | 0.42 | -1.14 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.72 | -0.77 | 0.42 | -1.14 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.70 | -0.77 | 0.42 | -1.09 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CYTK
- Portfolio NameUser Type
- Contributor$5 Stocks That Analysts Exp...
- UserBlue OAK
- UserDaveofDuke1111
- UserASCO 2010 Part 2
- ContributorBarron's Insider Purchases ...
- UserASCO 2009 Nymph's Watch List.
- UserHot Biotech Stocks II
- UserLet's Go Channeling
- UserDizziMage's Port
- Usermileslb Fidelity IRA
Latest CYTK Headlines from TheStreet
- Cytokinetics CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 11:10 pm
- $5 Stocks That Analysts Expect to Double 08.02.10 | 06:08 am
- Cytokinetics Inc. Q2 2010 Earnings Call Transcript 07.29.10 | 03:07 am
- Cytokinetics Ends Cancer Deal With GlaxoSmithKline 12.09.09 | 04:12 pm
- Movers Roundup: Manitowoc, Symantec 10.29.09 | 02:10 pm
- Cytokinetics Shares Fall On Drug Development Delay 10.29.09 | 12:10 pm
- Harmonic, SkyPeople: Midday Volume Plays 10.29.09 | 12:10 pm
- High Times
09.29.09 | 10:09 am - Cytokinetics: Pump Up The Volume 09.25.09 | 03:09 pm
- Optimer Soars on Antibiotic Data 11.11.08 | 12:11 pm
Press Releases for CYTK
Partner Headlines for CYTK
- Rodman & Renshaw Reiterates Cytokinetics Market Outperform, $4 PT - Benzinga 11.01.11 | 04:11 pm
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
- Cytokinetics Up 9% (CYTK) - Benzinga 04.12.11 | 09:04 am
- Cytokinetics: Most Recent Victim of Unjustified Biotech Sell-Off - Seeking Alpha 12.19.10 | 07:12 am
- UPDATE 1-Cytokinetics' Lou Gehrig's drug gets orphan status - Reuters 03.10.10 | 09:03 am
